Flxion Medical Files Patent for

Groundbreaking Injector Technology

 

A Major Step Forward in Emergency Medication Delivery

Flxion Medical is proud to announce the official filing of a new patent application with the United States Patent and Trademark Office (USPTO). This next-generation injector represents a significant leap forward in how emergency medications are administered—featuring a design that’s more intuitive, ergonomically optimized, and versatile than ever before.

 

Revolutionizing Emergency Care

In emergencies such as opioid overdoses or anaphylactic reactions, every second matters. Life-saving medications like Naloxone and Epinephrine must be delivered quickly and effectively—often through:

 

•Intramuscular (IM)

•Intranasal (IN)

•Intravenous (IV)

 

But what happens when intranasal delivery fails—due to nasal blockage or improper use? Without a reliable IM or IV backup, outcomes can turn fatal. That’s where our patent-pending InFlx™ Injector comes in. Three Delivery Routes. Countless Lives Saved. Our innovative proprietary injector is a low-cost device capable of delivering medication via IM, IN or IV—an unmatched level of flexibility for high-stakes scenarios.

 

Key Benefits:​

•Universal application across emergency use cases

•Designed for both professionals and lay users

•Compact, affordable, and intuitive to operate

•Minimizes failure risk from limited delivery options

 

A New Standard in Life-Saving Technology

This adaptable solution is engineered to replace outdated, single-route injectors. Whether you're a first responder or a bystander, the InFlx™ Injector ensures fast, reliable treatment when lives are on the line.

 

What’s Next

Once the patent is officially granted, Flxion Medical will make a full public announcement here on our website.

 

Stay tuned for updates—and be part of a future where no life is lost due to limited medication access.